Analytical Data
-
Gene name
CD180
- Application
-
Alternative Names
LY64; Ly78; RP105; Lymphocyte Antigen 64, Radioprotective 105kD
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q99467
-
Expression Region
Asp288~Asp620
-
Molecular Weight
38kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD180, also known as RP105, is a receptor primarily expressed on B cells and plays a crucial role in the regulation of immune responses. It belongs to the Toll-like receptor (TLR) family and is involved in the activation and maturation of B cells, contributing to the production of antibodies. Research on CD180 has gained momentum due to its potential implications in various diseases, including autoimmune disorders, infections, and cancers. Understanding the structure and function of CD180 can provide insights into its role in immune regulation and its potential as a therapeutic target. Recombinant CD180 protein offers a valuable tool for these studies, allowing researchers to investigate its signaling pathways, interactions with other receptors, and effects on B cell activation and proliferation. Additionally, recombinant CD180 may serve as a candidate for vaccine development or as a biomarker for disease progression. The exploration of CD180 not only deepens our understanding of B cell biology but also opens avenues for novel immunotherapeutic strategies. Given the complexity of immune responses and the involvement of CD180 in them, ongoing studies aim to elucidate its mechanisms and therapeutic potentials, paving the way for its application in clinical settings.
